{"id":16278,"date":"2017-12-13T19:11:22","date_gmt":"2017-12-13T19:11:22","guid":{"rendered":"https:\/\/sffd.ch\/a-propos-de-fabry\/traitement\/"},"modified":"2018-04-09T12:17:27","modified_gmt":"2018-04-09T12:17:27","slug":"traitement","status":"publish","type":"page","link":"https:\/\/sffd.ch\/fr\/a-propos-de-fabry\/traitement\/","title":{"rendered":"Traitement"},"content":{"rendered":"

[vc_row css_animation=\u00a0\u00bb\u00a0\u00bb row_type=\u00a0\u00bbrow\u00a0\u00bb use_row_as_full_screen_section=\u00a0\u00bbno\u00a0\u00bb type=\u00a0\u00bbfull_width\u00a0\u00bb angled_section=\u00a0\u00bbno\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb background_image_as_pattern=\u00a0\u00bbwithout_pattern\u00a0\u00bb][vc_column][vc_column_text]<\/p>\n

Traitement<\/h1>\n
\n
<\/div>\n
<\/div>\n
<\/div>\n<\/div>\n

[\/vc_column_text][vc_separator type=\u00a0\u00bbtransparent\u00a0\u00bb][\/vc_column][\/vc_row][vc_row css_animation=\u00a0\u00bb\u00a0\u00bb row_type=\u00a0\u00bbrow\u00a0\u00bb use_row_as_full_screen_section=\u00a0\u00bbno\u00a0\u00bb type=\u00a0\u00bbfull_width\u00a0\u00bb angled_section=\u00a0\u00bbno\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb background_image_as_pattern=\u00a0\u00bbwithout_pattern\u00a0\u00bb][vc_column][vc_column_text]1. Traitement symptomatique<\/span><\/p>\n

    \n
  • Acroparesth\u00e9sies: anti\u00e9pileptiques (carbamaz\u00e9pine ; ph\u00e9nytoine); parac\u00e9tamol ; AINS<\/li>\n
  • IRC : IECA ; sartan ; autres antihypertenseurs<\/li>\n
  • Cardiomyopathie : IECA ; diur\u00e9tiques\u2026antiarythmiques ; pacemaker ; prise en charge FRCV<\/li>\n
  • AIT\/AVC : aspirine cardio ; prise en charge FRCV<\/li>\n<\/ul>\n

     <\/p>\n

    2. Traitement enzymatique substitutif<\/span><\/p>\n

    Deux formulations d\u2019enzyme recombinante humaine -galactosidase A sont commercialis\u00e9es depuis 2001:<\/p>\n

      \n
    • l\u2019agalsidase alfa (Replagal\u00ae), d\u2019origine humaine<\/li>\n
    • l\u2019agalsidase beta (Fabrazyme\u00ae), d\u2019origine chim\u00e9rique (humaine et hamster)<\/li>\n<\/ul>\n

      Sur la base des \u00e9tudes cliniques \u00e0 disposition, leur efficacit\u00e9 clinique est probablement comparable.<\/p>\n

      Elles diff\u00e8rent principalement par leurs proc\u00e9d\u00e9s de fabrication, leur posologie, la dur\u00e9e de perfusion et leurs effets secondaires. Leur co\u00fbt annuel comparable, est prohibitif.<\/p>\n

      [\/vc_column_text][vc_separator type=\u00a0\u00bbtransparent\u00a0\u00bb][\/vc_column][\/vc_row][vc_row css_animation=\u00a0\u00bb\u00a0\u00bb row_type=\u00a0\u00bbrow\u00a0\u00bb use_row_as_full_screen_section=\u00a0\u00bbno\u00a0\u00bb type=\u00a0\u00bbfull_width\u00a0\u00bb angled_section=\u00a0\u00bbno\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb background_image_as_pattern=\u00a0\u00bbwithout_pattern\u00a0\u00bb][vc_column][vc_column_text]3. Migalastat<\/span><\/p>\n

      La premi\u00e8re th\u00e9rapie per os avec des mutations r\u00e9actives[\/vc_column_text][\/vc_column][\/vc_row][vc_row css_animation=\u00a0\u00bb\u00a0\u00bb row_type=\u00a0\u00bbrow\u00a0\u00bb use_row_as_full_screen_section=\u00a0\u00bbno\u00a0\u00bb type=\u00a0\u00bbfull_width\u00a0\u00bb angled_section=\u00a0\u00bbno\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb background_image_as_pattern=\u00a0\u00bbwithout_pattern\u00a0\u00bb][vc_column][vc_separator type=\u00a0\u00bbtransparent\u00a0\u00bb][\/vc_column][\/vc_row][vc_row css_animation=\u00a0\u00bb\u00a0\u00bb row_type=\u00a0\u00bbrow\u00a0\u00bb use_row_as_full_screen_section=\u00a0\u00bbno\u00a0\u00bb type=\u00a0\u00bbfull_width\u00a0\u00bb angled_section=\u00a0\u00bbno\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb background_image_as_pattern=\u00a0\u00bbwithout_pattern\u00a0\u00bb][vc_column][vc_widget_sidebar sidebar_id=\u00a0\u00bbsidebar\u00a0\u00bb][\/vc_column][\/vc_row][vc_row css_animation=\u00a0\u00bb\u00a0\u00bb row_type=\u00a0\u00bbrow\u00a0\u00bb use_row_as_full_screen_section=\u00a0\u00bbno\u00a0\u00bb type=\u00a0\u00bbfull_width\u00a0\u00bb angled_section=\u00a0\u00bbno\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb background_image_as_pattern=\u00a0\u00bbwithout_pattern\u00a0\u00bb][vc_column][vc_separator type=\u00a0\u00bbtransparent\u00a0\u00bb][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

      [vc_row css_animation=\u00a0\u00bb\u00a0\u00bb row_type=\u00a0\u00bbrow\u00a0\u00bb use_row_as_full_screen_section=\u00a0\u00bbno\u00a0\u00bb type=\u00a0\u00bbfull_width\u00a0\u00bb angled_section=\u00a0\u00bbno\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb background_image_as_pattern=\u00a0\u00bbwithout_pattern\u00a0\u00bb][vc_column][vc_column_text] Traitement [\/vc_column_text][vc_separator type=\u00a0\u00bbtransparent\u00a0\u00bb][\/vc_column][\/vc_row][vc_row css_animation=\u00a0\u00bb\u00a0\u00bb row_type=\u00a0\u00bbrow\u00a0\u00bb use_row_as_full_screen_section=\u00a0\u00bbno\u00a0\u00bb type=\u00a0\u00bbfull_width\u00a0\u00bb angled_section=\u00a0\u00bbno\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb background_image_as_pattern=\u00a0\u00bbwithout_pattern\u00a0\u00bb][vc_column][vc_column_text]1. Traitement symptomatique Acroparesth\u00e9sies: anti\u00e9pileptiques (carbamaz\u00e9pine ; ph\u00e9nytoine); parac\u00e9tamol ; AINS IRC : IECA ; sartan ; autres antihypertenseurs Cardiomyopathie : IECA ; diur\u00e9tiques\u2026antiarythmiques ; pacemaker ; prise…<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":16246,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-16278","page","type-page","status-publish","hentry"],"yoast_head":"\nTraitement - SFFD<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sffd.ch\/fr\/a-propos-de-fabry\/traitement\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Traitement - SFFD\" \/>\n<meta property=\"og:description\" content=\"[vc_row css_animation=\u00a0\u00bb\u00a0\u00bb row_type=\u00a0\u00bbrow\u00a0\u00bb use_row_as_full_screen_section=\u00a0\u00bbno\u00a0\u00bb type=\u00a0\u00bbfull_width\u00a0\u00bb angled_section=\u00a0\u00bbno\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb background_image_as_pattern=\u00a0\u00bbwithout_pattern\u00a0\u00bb][vc_column][vc_column_text] Traitement [\/vc_column_text][vc_separator type=\u00a0\u00bbtransparent\u00a0\u00bb][\/vc_column][\/vc_row][vc_row css_animation=\u00a0\u00bb\u00a0\u00bb row_type=\u00a0\u00bbrow\u00a0\u00bb use_row_as_full_screen_section=\u00a0\u00bbno\u00a0\u00bb type=\u00a0\u00bbfull_width\u00a0\u00bb angled_section=\u00a0\u00bbno\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb background_image_as_pattern=\u00a0\u00bbwithout_pattern\u00a0\u00bb][vc_column][vc_column_text]1. Traitement symptomatique Acroparesth\u00e9sies: anti\u00e9pileptiques (carbamaz\u00e9pine ; ph\u00e9nytoine); parac\u00e9tamol ; AINS IRC : IECA ; sartan ; autres antihypertenseurs Cardiomyopathie : IECA ; diur\u00e9tiques\u2026antiarythmiques ; pacemaker ; prise...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sffd.ch\/fr\/a-propos-de-fabry\/traitement\/\" \/>\n<meta property=\"og:site_name\" content=\"SFFD\" \/>\n<meta property=\"article:modified_time\" content=\"2018-04-09T12:17:27+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/sffd.ch\\\/fr\\\/a-propos-de-fabry\\\/traitement\\\/\",\"url\":\"https:\\\/\\\/sffd.ch\\\/fr\\\/a-propos-de-fabry\\\/traitement\\\/\",\"name\":\"Traitement - SFFD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/sffd.ch\\\/#website\"},\"datePublished\":\"2017-12-13T19:11:22+00:00\",\"dateModified\":\"2018-04-09T12:17:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/sffd.ch\\\/fr\\\/a-propos-de-fabry\\\/traitement\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/sffd.ch\\\/fr\\\/a-propos-de-fabry\\\/traitement\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/sffd.ch\\\/fr\\\/a-propos-de-fabry\\\/traitement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/sffd.ch\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u00c0 propos de Fabry\",\"item\":\"https:\\\/\\\/sffd.ch\\\/fr\\\/a-propos-de-fabry\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Traitement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/sffd.ch\\\/#website\",\"url\":\"https:\\\/\\\/sffd.ch\\\/\",\"name\":\"SFFD\",\"description\":\"Swiss Foundation of Fabry Disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/sffd.ch\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Traitement - SFFD","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sffd.ch\/fr\/a-propos-de-fabry\/traitement\/","og_locale":"fr_FR","og_type":"article","og_title":"Traitement - SFFD","og_description":"[vc_row css_animation=\u00a0\u00bb\u00a0\u00bb row_type=\u00a0\u00bbrow\u00a0\u00bb use_row_as_full_screen_section=\u00a0\u00bbno\u00a0\u00bb type=\u00a0\u00bbfull_width\u00a0\u00bb angled_section=\u00a0\u00bbno\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb background_image_as_pattern=\u00a0\u00bbwithout_pattern\u00a0\u00bb][vc_column][vc_column_text] Traitement [\/vc_column_text][vc_separator type=\u00a0\u00bbtransparent\u00a0\u00bb][\/vc_column][\/vc_row][vc_row css_animation=\u00a0\u00bb\u00a0\u00bb row_type=\u00a0\u00bbrow\u00a0\u00bb use_row_as_full_screen_section=\u00a0\u00bbno\u00a0\u00bb type=\u00a0\u00bbfull_width\u00a0\u00bb angled_section=\u00a0\u00bbno\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb background_image_as_pattern=\u00a0\u00bbwithout_pattern\u00a0\u00bb][vc_column][vc_column_text]1. Traitement symptomatique Acroparesth\u00e9sies: anti\u00e9pileptiques (carbamaz\u00e9pine ; ph\u00e9nytoine); parac\u00e9tamol ; AINS IRC : IECA ; sartan ; autres antihypertenseurs Cardiomyopathie : IECA ; diur\u00e9tiques\u2026antiarythmiques ; pacemaker ; prise...","og_url":"https:\/\/sffd.ch\/fr\/a-propos-de-fabry\/traitement\/","og_site_name":"SFFD","article_modified_time":"2018-04-09T12:17:27+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/sffd.ch\/fr\/a-propos-de-fabry\/traitement\/","url":"https:\/\/sffd.ch\/fr\/a-propos-de-fabry\/traitement\/","name":"Traitement - SFFD","isPartOf":{"@id":"https:\/\/sffd.ch\/#website"},"datePublished":"2017-12-13T19:11:22+00:00","dateModified":"2018-04-09T12:17:27+00:00","breadcrumb":{"@id":"https:\/\/sffd.ch\/fr\/a-propos-de-fabry\/traitement\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sffd.ch\/fr\/a-propos-de-fabry\/traitement\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/sffd.ch\/fr\/a-propos-de-fabry\/traitement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/sffd.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"\u00c0 propos de Fabry","item":"https:\/\/sffd.ch\/fr\/a-propos-de-fabry\/"},{"@type":"ListItem","position":3,"name":"Traitement"}]},{"@type":"WebSite","@id":"https:\/\/sffd.ch\/#website","url":"https:\/\/sffd.ch\/","name":"SFFD","description":"Swiss Foundation of Fabry Disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sffd.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/sffd.ch\/fr\/wp-json\/wp\/v2\/pages\/16278","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sffd.ch\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/sffd.ch\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/sffd.ch\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/sffd.ch\/fr\/wp-json\/wp\/v2\/comments?post=16278"}],"version-history":[{"count":12,"href":"https:\/\/sffd.ch\/fr\/wp-json\/wp\/v2\/pages\/16278\/revisions"}],"predecessor-version":[{"id":16625,"href":"https:\/\/sffd.ch\/fr\/wp-json\/wp\/v2\/pages\/16278\/revisions\/16625"}],"up":[{"embeddable":true,"href":"https:\/\/sffd.ch\/fr\/wp-json\/wp\/v2\/pages\/16246"}],"wp:attachment":[{"href":"https:\/\/sffd.ch\/fr\/wp-json\/wp\/v2\/media?parent=16278"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}